Understanding PLET1: A Potential Drug Target and Biomarker (G349633)

Target Name: PLET1

NCBI ID: G349633

PLET1

Understanding PLET1: A Potential Drug Target and Biomarker

PLET1 (C11orf34) is a gene that has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique genetic mutation has led to a wide range of biological processes that have not yet been fully understood, but research into its potential drug targets and biomarkers is ongoing.

The PLET1 gene was identified in 2008 as a potential gene that could be targeted for cancer treatment. The gene is located on chromosome 11 and has been shown to be involved in the development and progression of several types of cancer, including breast, ovarian, and prostate cancer. PLET1 has also been shown to be involved in the regulation of cell growth and division, which are critical processes that are often disrupted in cancer cells.

Since its identification, research into PLET1 has focused on its potential drug targets and biomarkers. One of the main goals of research into PLET1 is to identify small molecules that can interact with the PLET1 gene and prevent or reverse its negative effects on cancer cells. This is an important area of research because the majority of cancer deaths are caused by the development of new tumors, and there is a high demand for new and effective treatments.

Another important area of research into PLET1 is its potential as a biomarker for cancer. The PLET1 gene has been shown to be expressed in a wide range of tissues and cells, including cancer cells, normal cells, and immune cells. This makes it an attractive candidate for use as a biomarker for cancer, as it can be used to diagnose and monitor the effectiveness of cancer treatments.

In addition to its potential drug and biomarker applications, PLET1 has also been shown to be involved in the regulation of several other biological processes that are important for human health. For example, PLET1 has been shown to be involved in the development and maintenance of the nervous system, which is responsible for transmitting and processing information. This is important for maintaining the body's ability to function and communicate, and is an important area of research in neurodegenerative diseases.

PLET1 has also been shown to be involved in the regulation of the immune system, which is responsible for protecting the body against infection and disease. This is important for maintaining the body's ability to fight off infections and cancer, and is an important area of research in autoimmune disorders.

In conclusion, PLET1 is a gene that has significant potential as a drug target and biomarker for several diseases. Its unique genetic mutation and involvement in a wide range of biological processes make it an attractive candidate for further research. As research continues, it is likely that new insights into the biology of PLET1 will emerge, and its potential as a drug and biomarker will be further validated.

Protein Name: Placenta Expressed Transcript 1

Functions: Modulates leading keratinocyte migration and cellular adhesion to matrix proteins during a wound-healing response and promotes wound repair. May play a role during trichilemmal differentiation of the hair follicle (By similarity)

The "PLET1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLET1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets